Form 4 for AKTX Akari Therapeutics Plc
Accepted 2024-07-02 00:00:00 ET · period of report 2024-06-30 · accession 0000950170-24-080542 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-02 | 2024-06-30 | AKTX | Patel Samir Rashmikant | Dir | A - Grant | $0.00 | +91.40M | 91.40M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares, par value $0.0001 per share | 2024-06-30 | A | A | 91,396,000 | $0.00 | 91,396,000 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. (F2) These shares represent restricted stock units ("RSUs") granted under the Issuer's 2023 Equity Incentive Plan, with each such RSU representing the right to receive one ordinary share, par value $0.0001. One-hundered percent (100%) of the RSUs vested on the date of grant, or June 30, 2024. |